Potentiating cancer vaccination by adjuvant-loaded cryo-shocked tumor cells

Mo Chen; Huangjuan Li; Jing Zang; Yueyang Deng; Hongjun Li; Qing Wu; Tianyuan Ci; Zhen Gu

doi:10.1016/j.biomaterials.2023.122319

Potentiating cancer vaccination by adjuvant-loaded cryo-shocked tumor cells

Biomaterials. 2023 Nov:302:122319. doi: 10.1016/j.biomaterials.2023.122319. Epub 2023 Sep 11.

Authors

Mo Chen¹, Huangjuan Li², Jing Zang³, Yueyang Deng², Hongjun Li⁴, Qing Wu⁴, Tianyuan Ci⁵, Zhen Gu⁶

Affiliations

¹ Department of Pharmaceutical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu province, 210009, China.
² Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu province, 210009, China.
³ Department of Pharmaceutical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
⁴ College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
⁵ Department of Pharmaceutical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address: tianyuanci@shutcm.edu.cn.
⁶ College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China; Department of Bioengineering, University of California, Los Angeles, CA, 90095, USA; Liangzhu Laboratory, Zhejiang University Medical Center, Sir Run Run Shaw Hospital, Hangzhou, 310058, China; Jinhua Institute of Zhejiang University, Jinhua, 321299, China; Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China. Electronic address: guzhen@zju.edu.cn.

PMID: 37741150
DOI: 10.1016/j.biomaterials.2023.122319

Abstract

Cancer vaccine holds vast promise in potentiating tumor immunotherapy. Here, we developed a simple cancer vaccine based on the liquid nitrogen-treated cells (LNT cells) that engineered by one-shot shocking of the live tumor cells in liquid nitrogen. In this vaccine, the obtained LNT cells served as both tumor antigens and delivery vehicles to load the adjuvant imiquimod (R837). This design could achieve efficient co-uptake of antigen/adjuvant by antigen presenting cells (APCs) and prolong in vivo retention of tumor antigens and adjuvants. This adjuvant-loaded LNT cells augmented in vivo antitumor responses and enhanced survival in melanoma-bearing mouse model compared with conventional whole-cell vaccine of the mixture of tumor lysis and adjuvant.

Keywords: Cancer vaccine; Cell therapy; Drug delivery; Immunotherapy; Liquid nitrogen-treated cells.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic / pharmacology
Animals
Antigens, Neoplasm
Cancer Vaccines* / therapeutic use
Dendritic Cells
Immunotherapy
Melanoma*
Mice
Nitrogen
Vaccination

Substances

Cancer Vaccines
Adjuvants, Immunologic
Antigens, Neoplasm
Nitrogen